FRI-470 - HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study
Alkhouri, Naim, Liu, Yongheng, Liang, Nian, Zhai, Peibin, Wu, Sandra, Zhou, Xin, Xu, Michael, Liu, Que, Harrison, Stephen
Published in Journal of hepatology (01.06.2023)
Published in Journal of hepatology (01.06.2023)
Get full text
Journal Article
HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study
Alkhouri, Naim, Liu, Yongheng, Liang, Nian, Zhai, Peibin, Wu, Sandra, Zhou, Xin, Xu, Michael, Liu, Que, Harrison, Stephen
Published in Journal of hepatology (01.06.2023)
Published in Journal of hepatology (01.06.2023)
Get full text
Journal Article
WED-510 - Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis
Xu, Michael, Chen, Shijia, Guo, Fang, Liu, Que, Liu, Yongheng, Mo, Cheng, Peng, Yihong, Xiong, Yating, Zhai, Peibin, Zhang, Pan, Zhao, Xinpeng, Zhou, Xin, Chu, Xin-Jie
Published in Journal of hepatology (01.06.2023)
Published in Journal of hepatology (01.06.2023)
Get full text
Journal Article
Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis
Xu, Michael, Chen, Shijia, Guo, Fang, Liu, Que, Liu, Yongheng, Mo, Cheng, Peng, Yihong, Xiong, Yating, Zhai, Peibin, Zhang, Pan, Zhao, Xinpeng, Zhou, Xin, Chu, Xin-Jie
Published in Journal of hepatology (01.06.2023)
Published in Journal of hepatology (01.06.2023)
Get full text
Journal Article